Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00463814 · ClinicalTrials.gov registry record · Phase 1
AZD6244 (ARRY-142886) Solid Oral Dosage Formulation in Participants With Advanced Solid Malignancies
A Phase 1 study of Cancer and Tumor, sponsored by AstraZeneca.
- Active
- Registry status
- Phase 1
- Development phase
- 58
- Enrollment target
- 4
- Study locations
NCT00463814 is a Phase 1 study of Cancer and Tumor that is active but no longer recruiting, run by AstraZeneca. The registered enrollment target is 58 participants, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (98% lower). The trial reports 4 study locations across 2 states.
The verdict
NCT00463814, a Phase 1 study of Cancer and Tumor, is active but no longer recruiting, sponsored by AstraZeneca.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 58 participants
- Enrollment target
- 4
- Study locations
Study Summary
The primary purpose of the study is to assess the safety, tolerability and pharmacokinetics of a capsule of AZD6244 in participants with advanced solid malignancies.
Interventions
- DRUG AZD6244
Study Locations (4)
Other
- Research Site - Nijmegen
- Research Site - Utrecht
- Research Site - Sutton
Colorado
- Research Site - Aurora
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 58 participants |
| Start Date | 2007-03-08 |
| Est. Completion | 2025-12-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00463814
The ClinicalTrials.gov registry entry for NCT00463814 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 58 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (98% lower). The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Cancer appearing as the primary indexed condition, and to 1 intervention - of which AZD6244 is the first listed.
NCT00463814 reports 4 study locations spanning 2 distinct geographic areas - top geographies include Other, Colorado.
Frequently Asked Questions
What is clinical trial NCT00463814 about?
NCT00463814 is a clinical study titled "AZD6244 (ARRY-142886) Solid Oral Dosage Formulation in Participants With Advanced Solid Malignancies". The primary purpose of the study is to assess the safety, tolerability and pharmacokinetics of a capsule of AZD6244 in participants with advanced solid malignancies.
What is the current status of trial NCT00463814?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 58 participants. The study started on 2007-03-08. Estimated completion is 2025-12-31.
What conditions does trial NCT00463814 study?
This clinical trial studies the following conditions: Cancer, Tumor.
What interventions are being tested in trial NCT00463814?
The interventions under investigation include: AZD6244 (DRUG).
Who is sponsoring clinical trial NCT00463814?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00463814 being conducted?
This trial has 4 study locations across Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With Cancer
RECRUITING · Phase 1
-
A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents
RECRUITING · Phase 1
-
A Phase 1 Study of CPO301 in Adult Patients With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Impact of Daily Oral Cannabis Doses in Patients With Cancer
RECRUITING · Phase 1
-
A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Safety, PK, and Preliminary Efficacy of MBRC-101 in Advanced Refractory Solid Tumors
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.